BioGaia AB (publ) (LON:0GTN)

Market Cap	914.07M -1.2%
Revenue (ttm)	123.99M +8.1%
Net Income	26.82M -5.3%
EPS	0.27 -5.4%
Shares Out	n/a
PE Ratio	34.08
Forward PE	27.12
Dividend	0.54 (0.47%)
Ex-Dividend Date	May 8, 2025

Volume	2,396
Average Volume	22,382
Open	113.70
Previous Close	117.64
Day's Range	112.94 - 114.10
52-Week Range	93.60 - 119.50
Beta	0.43
RSI	55.29
Earnings Date	Jul 17, 2026

About BioGaia AB

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. The Adult Health segment provides gut health tablets, bone health tablet...

• Industry: Pharmaceutical Preparations
• Founded: 1990
• Employees: 242
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0GTN

Financial Performance

In 2025, BioGaia AB's revenue was 1.54 billion, an increase of 8.11% compared to the previous year's 1.42 billion. Earnings were 332.76 million, a decrease of -5.30%.

Financial numbers in SEK